



## **MEDIA RELEASE**

# **QT VASCULAR ANNOUNCES CHOCOLATE® PTA CATHETER SHONIN SUBMITTED IN JAPAN**

### ***Highlights:***

- **Incidence of peripheral vascular disease and interventional treatments growing in Japan**
- **Chocolate® PTA catheter has been shown to reduce the need for unplanned stenting**

**SINGAPORE, 1 April 2015 – QT Vascular Ltd.**, together with its subsidiaries (“**QT Vascular**” or the “**Group**”), a global company engaged in the design, assembly and distribution of advanced therapeutic solutions for the minimally invasive treatment of vascular disease, today announced that its distribution partner, Century Medical, Inc. (CMI), has submitted the Shonin (application for regulatory approval) for Chocolate® PTA balloon catheter in Japan.

The Chocolate® PTA catheter is a novel device designed to dilate diseased peripheral vessels in a less traumatic way compared to conventional balloon angioplasty. It utilizes a unique constraining element on the outside of the balloon that reduces the stress the vessel experiences during inflation and forces the balloon to expand in a uniform manner. By reducing acute trauma, Chocolate® PTA is able to reduce severe dissections and thus reduce the need for unplanned stenting compared to conventional balloons<sup>(1)</sup>.

“Chocolate® PTA is a unique device that has shown the potential to improve clinical outcomes,” stated Mr. Akira Hoshino, President and CEO of CMI. “This submission of the Shonin application represents a significant milestone as we at Century Medical, Inc. build our endovascular business.”

The Chocolate® PTA also acts as the platform for the Group’s novel drug-coated balloon, Chocolate Touch. With the addition of the proven drug, paclitaxel, to the low trauma Chocolate® platform, Chocolate Touch offers the potential to address one of the major limitations of current

drug-coated balloons; acute trauma which leads to dissections and unplanned stenting. In a recent publication, the incidence of unplanned stenting with drug-coated balloons in an unrestricted, real world environment is up to 25%<sup>(2)</sup>.

“This submission of the Shonin application to the regulatory authorities in Japan is a critical step for us to broaden the availability of Chocolate® to one of the largest and most significant markets”, stated Dr. Eitan Konstantino, Ph.D., Chief Executive Officer of QT Vascular. “This expected approval in Japan is complemented by the expected approval of the Chocolate Touch in Europe later this year.”

<sup>(1)</sup> Dr. Tony Das, et al. “Chocolate® BAR: Chocolate PTA in a broad range of patients with PAD, a prospective post-marketing study”, LINC 2014

<sup>(2)</sup> Dr. Gary Ansel, “IN.PACT Global First Report 12-Month Outcomes (655 Subjects)”, TCT 2014

~~ End ~~

**ABOUT QT VASCULAR LTD.**

(SGX Stock code: 510, Bloomberg Code: QTVC SP, Reuters Code: QTVA.SI)

**QT Vascular Ltd.** together with its subsidiaries (“**QT Vascular**” or the “**Group**”) is an emerging leader in the development and commercialization of next generation minimally invasive products for the treatment of complex vascular disease. The Company works closely with leading physicians and scientists from around the world to create differentiated devices that improve procedural and clinical outcomes.

QT Vascular is based in Singapore with a US subsidiary, TriReme Medical LLC, based in Pleasanton, California. Its vascular solution products include a range of percutaneous transluminal angioplasty (“**PTA**”) and percutaneous transluminal coronary angioplasty (“**PTCA**”) products.

With the exception of its direct sales of its coronary products (Chocolate<sup>®</sup> PTCA Balloon Catheter and Glider<sup>™</sup> PTCA Balloon Catheter) in the United States, these products are sold through its main distributors: (i) Cordis Corporation (a wholly-owned subsidiary of Johnson & Johnson), (ii) Shandong Weigao Group Medical Polymer Co Ltd and (iii) Century Medical, Inc.

The Group is also applying for CE mark approval with respect to the Chocolate<sup>®</sup> Touch, its advanced drug-coated peripheral balloon.

For more information, please visit the company website at [www.qtvascular.com](http://www.qtvascular.com)

---

Issued on behalf of **QT VASCULAR LTD.** by:

---

**WATERBROOKS CONSULTANTS PTE LTD**

Tel: +65 6100 2228

***For media and analysts, please contact:***

Mr Wayne Koo (M): +65 9338 8166 [wayne.koo@waterbrooks.com.sg](mailto:wayne.koo@waterbrooks.com.sg)

Ms Lynette Tan (M): +65 9687 2023 [lynette@waterbrooks.com.sg](mailto:lynette@waterbrooks.com.sg)

Ms Angeline Cheong (M): +65 9666 0977 [angeline@waterbrooks.com.sg](mailto:angeline@waterbrooks.com.sg)

---

***Cautionary Note on Forward-Looking Statements***

*All statements other than statements of historical facts included in this announcement are or may be forward-looking statements. Forward-looking statements include but are not limited to those using words such as “expect”, “anticipate”, “believe”, “estimate”, “intend”, “project”, “plan”, “strategy”, “forecast” and similar expressions or future or conditional verbs such as “if”, “will”, “would”, “should”, “could”, “may” and “might”. These statements reflect the Company’s current expectations, beliefs, hopes, intentions or strategies regarding the future and assumptions in*

*light of currently available information. Such forward-looking statements are not guarantees of future performance or events and involve known and unknown risks and uncertainties. Accordingly, actual results may differ materially from those described in such forward-looking statements. Shareholders should not place undue reliance on such forward-looking statements, and the Company undertakes any obligation to update publicly or revise any forward-looking statements, subject to compliance with all applicable laws and regulations and/or the rules of the SGX-ST and/or any other regulatory or supervisory body or agency.*

*QT Vascular Ltd. (the "Company") was listed on Catalist board of the Singapore Exchange Securities Trading Limited (the "SGX-ST") on 29 April 2014. The initial public offering of the Company was sponsored by PrimePartners Corporate Finance Pte. Ltd. (the "Sponsor").*

*This press release has been prepared by the Company and its contents have been reviewed by the Sponsor for compliance with the SGX-ST Listing Manual Section B: Rules of Catalist. The Sponsor has not verified the contents of this press release.*

*This press release has not been examined or approved by the SGX-ST. The Sponsor and the SGX-ST assume no responsibility for the contents of this press release including the accuracy, completeness or correctness of any of the information, statements or opinions made or reports contained in this press release.*

*The contact person for the Sponsor is Ms Gillian Goh, Director, Head of Continuing Sponsorship, at 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318, telephone +65 6229 8088.*